Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by COLIN P DINNEY and WOONYOUNG CHOI.
COLIN P DINNEY
Connection Strength
1.367
WOONYOUNG CHOI
  1. TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. Mol Cancer Res. 2020 06; 18(6):811-821.
    View in: PubMed
    Score: 0.178
  2. Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. Oncoimmunology. 2019; 8(5):e1577125.
    View in: PubMed
    Score: 0.166
  3. Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget. 2017 May 23; 8(21):34205-34222.
    View in: PubMed
    Score: 0.147
  4. Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sj?dahl, and Mattias H?glund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10. Eur Urol. 2015 Apr; 67(4):e76-8.
    View in: PubMed
    Score: 0.122
  5. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014 Jul; 11(7):400-10.
    View in: PubMed
    Score: 0.120
  6. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol. 2014 Oct; 66(4):609-10.
    View in: PubMed
    Score: 0.119
  7. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65.
    View in: PubMed
    Score: 0.117
  8. Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery. Transl Oncol. 2025 Jan 13; 52:102269.
    View in: PubMed
    Score: 0.062
  9. Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis. Cell Rep. 2024 05 28; 43(5):114146.
    View in: PubMed
    Score: 0.059
  10. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021 09; 206(3):548-557.
    View in: PubMed
    Score: 0.048
  11. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020 06 16; 10(1):9743.
    View in: PubMed
    Score: 0.045
  12. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
    View in: PubMed
    Score: 0.045
  13. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 02 19; 26(8):2241-2256.e4.
    View in: PubMed
    Score: 0.041
  14. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget. 2016 Dec 06; 7(49):80164-80174.
    View in: PubMed
    Score: 0.036
  15. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016 10; 70(4):611-620.
    View in: PubMed
    Score: 0.034
  16. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther. 2012 May; 13(7):477-86.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.